

# PEER-REVIEW REPORT

Name of journal: World Journal of Clinical Cases

Manuscript NO: 78285

Title: Conversion Therapy for Advanced Penile Cancer with Tislelizumab Combined

with Chemotherapy: A Case Report and Literature Review

Provenance and peer review: Unsolicited Manuscript; Externally peer reviewed

Peer-review model: Single blind

Reviewer's code: 02544209 Position: Editorial Board Academic degree: MD, PhD

**Professional title:** Professor

Reviewer's Country/Territory: Turkey

Author's Country/Territory: China

Manuscript submission date: 2022-06-18

Reviewer chosen by: AI Technique

Reviewer accepted review: 2022-07-11 21:50

Reviewer performed review: 2022-07-12 19:34

Review time: 21 Hours

Scientific quality	[ ] Grade A: Excellent [Y] Grade B: Very good [ ] Grade C: Good [ ] Grade D: Fair [ ] Grade E: Do not publish
Language quality	[ ] Grade A: Priority publishing [ Y] Grade B: Minor language polishing [ ] Grade C: A great deal of language polishing [ ] Grade D: Rejection
Conclusion	[ ] Accept (High priority) [ Y] Accept (General priority) [ ] Minor revision [ ] Major revision [ ] Rejection
Re-review	[ ]Yes [Y]No



https://www.wjgnet.com

Peer-reviewer	Peer-Review: [Y] Anonymous [ ] Onymous
statements	Conflicts-of-Interest: [ ] Yes [ Y] No

### SPECIFIC COMMENTS TO AUTHORS

The authors may add the pharmacological name of the EGFR inhibitors used in this case.



# PEER-REVIEW REPORT

Name of journal: World Journal of Clinical Cases

Manuscript NO: 78285

Title: Conversion Therapy for Advanced Penile Cancer with Tislelizumab Combined

with Chemotherapy: A Case Report and Literature Review

Provenance and peer review: Unsolicited Manuscript; Externally peer reviewed

Peer-review model: Single blind

Reviewer's code: 05481632 Position: Peer Reviewer Academic degree: MCh

**Professional title:** Assistant Professor

Reviewer's Country/Territory: India

Author's Country/Territory: China

Manuscript submission date: 2022-06-18

Reviewer chosen by: Dong-Mei Wang

Reviewer accepted review: 2022-08-17 05:34

Reviewer performed review: 2022-08-18 15:50

**Review time:** 1 Day and 10 Hours

Scientific quality	[ ] Grade A: Excellent [ ] Grade B: Very good [ ] Grade C: Good [ Y] Grade D: Fair [ ] Grade E: Do not publish
Language quality	[ ] Grade A: Priority publishing [ ] Grade B: Minor language polishing [ Y] Grade C: A great deal of language polishing [ ] Grade D: Rejection
Conclusion	[ ] Accept (High priority) [ ] Accept (General priority) [ ] Minor revision [ Y] Major revision [ ] Rejection
Re-review	[Y]Yes []No



# Baishideng Publishing

7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

**Telephone:** +1-925-399-1568 **E-mail:** bpgoffice@wjgnet.com

https://www.wjgnet.com

Peer-reviewer

Peer-Review: [Y] Anonymous [] Onymous

statements

Conflicts-of-Interest: [ ] Yes [Y] No

### SPECIFIC COMMENTS TO AUTHORS

A good use of combination therapy with immunotherapy and chemotherapy, but the case report is let down by the large number of grammatical errors Was a ethical committee clearance obtained? as this is not the standard of care and is an experimental therapy



# PEER-REVIEW REPORT

Name of journal: World Journal of Clinical Cases

Manuscript NO: 78285

Title: Conversion Therapy for Advanced Penile Cancer with Tislelizumab Combined

with Chemotherapy: A Case Report and Literature Review

Provenance and peer review: Unsolicited Manuscript; Externally peer reviewed

Peer-review model: Single blind

Reviewer's code: 05480683 Position: Peer Reviewer Academic degree: PhD

Professional title: Academic Fellow, Academic Research, Adjunct Professor

Reviewer's Country/Territory: Italy
Author's Country/Territory: China

Manuscript submission date: 2022-06-18

Reviewer chosen by: Dong-Mei Wang

Reviewer accepted review: 2022-08-17 17:11

Reviewer performed review: 2022-08-21 08:30

**Review time:** 3 Days and 15 Hours

Scientific quality	[ ] Grade A: Excellent [ ] Grade B: Very good [ ] Grade C: Good [ Y] Grade D: Fair [ ] Grade E: Do not publish
Language quality	[ ] Grade A: Priority publishing [ Y] Grade B: Minor language polishing [ ] Grade C: A great deal of language polishing [ ] Grade D: Rejection
Conclusion	[ ] Accept (High priority) [ ] Accept (General priority) [ ] Minor revision [ Y] Major revision [ ] Rejection
Re-review	[Y]Yes []No



https://www.wignet.com

Peer-reviewer

Peer-Review: [Y] Anonymous [] Onymous

statements Conflicts-of-Interest: [ ] Yes [Y] No

### SPECIFIC COMMENTS TO AUTHORS

The case report entitled "Tislelizumab Combination with Chemotherapy Successfully Converted Unresectable Advanced Penile cancer into Complete Surgical Excision: A Case Report and Literature Review" by Dr. Long and colleagues, reports on a case of a58-year-old male with locally advanced Penile squamous cell carcinoma (PSCC). with bulky, fixed inguinal lymph node metastasis complicated within genial skin ulcers, who completed inguinal lymph node dissection and achieved pathologically complete response via conversion therapy by immunotherapy plus chemotherapy. The text is in general interesting, clear and easy to follow. However, more introductive notions should be included. Moreover, more supporting references and notions in the field should be and I am therefore recommending a major included. I have a several observations, revision(please see below for additional comments for improving the ms). Comments 1. More information on Penile cancer etiopathogenesis, mutational burden, therapy and prognosis should be included. For instance, a fraction of cases are HPV-driven. 2. More supporting references should be included, for instance here "but multiple small size cohort studies have demonstrated that nearly half of patients do not benefit from neoadjuvant chemotherapy alone, which made it urgent to find new and effective treatments." However, additional sentences spread throughout the text are lacking in supporting references 3. immune checkpoint inhibitors (ICIs) represent a promising therapeutic approach as stated (DOI: 10.3389/fonc.2022.832047). For completeness of information, this notion and supporting reference should eb included 4. Introduction the correct name is Programmed cell death protein 1 (PD-1) 5. Sections should be separated with a space 6. CASE PRESENTATION section, "21 days after surgery" I



discourage starting a sentence with a number 7. Figure 1 is not mentioned in the text, while it should be mentioned and described 8. Several sentence are in gray instead of black. Please fix this problem